News from Standout Stocks

3/5/2009 8:49 AM

Penny Stocks by: Standout Stocks

Buy CABN Online for $0. Trade stocks for free on Zecco.com.

Stocks That Standout Newsletter ~~~~~~~~~~~~~~~~~~~~~~~~~~

main banner ~~~~~~~~~~~~~~~~~~~~~~~~~~

Issue: # 235 March 5th, 2009 ~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

Greetings! Quotes about Patience "All things come to him who waits - provided he knows what he is waiting for." -Woodrow T. Wilson "Everything comes gradually and at its appointed hour." -Ovid "If you add a little to a little, and then do it again, soon that little shall be much." -Hesiod ~~~~~~~~~~~~~~~~~~~~~~~~~~

Today`s News CABN Carbon Sciences, Inc.

CABN Website Finance Stock Chart March 5th, 2009 Carbon Sciences Inc. (OTCBB: CABN), the developer of a breakthrough technology to transform carbon dioxide (CO2) emissions into gasoline and other fuels, today announced the launch of an updated website that reflects its market potential and key advantages over other renewable fuel technologies. The website describes how the Company`s breakthrough technology has the potential to produce more than 30% of global liquid fuel supply using less than half of the CO2 emissions from coal-fired power plants.

With global population projected to increase from 6.5 billion in 2006 to 8.5 billion by 2030, the Energy Information Administration (EIA) estimates that worldwide energy consumption will increase by 50% in the same period. This increase translates to a consumption of over 112 million barrels of crude oil per day, up from the recent 90 million barrels. Concurrently, annual CO2 emissions will increase from 29 billion tons in 2006 to 43 billion tons by 2030. The largest and most concentrated source of CO2 emissions is the growing use of coal-fired power plants, due to the low cost and abundance of coal.

Unlike other renewable fuel technologies, Carbon Sciences` CO2-to-Fuel technology transforms CO2 directly into renewable fuels that are identical to gasoline and other fuels in use today. Based on a scenario of using only 40% of CO2 emissions from coal-fired power plants in 2030, Carbon Sciences` technology can produce nearly 30% of the world`s liquid fuel supply and mitigate 11% of the world`s CO2 emissions.

Carbon Sciences believes that coal-fired power plants will not disappear anytime soon, but the problem of their massive CO2 emissions must be addressed immediately.

The only other approach to CO2 mitigation contemplated today is sequestering, or burying, CO2 in underground caverns and the ocean. Carbon Sciences believes that this is a dangerous and expensive solution, as demonstrated by the Energy Department`s 2008 rejection of a $112 million carbon sequestration proposal to reduce 60% of CO2 emissions from the Capitol Power Plant, which provides electricity to the U.

S. Congress and other capitol buildings.

Byron Elton, President and COO of Carbon Sciences, commented: "The most viable and sustainable solution to the energy and climate challenge is the direct and rapid transformation of CO2 into fuel. Our CO2-to-Fuel technology is being developed with that goal in mind. Our updated website describes our market potential and key advantages. No other approach, including biodiesel or cellulosic ethanol, can match our impact in addressing the energy and climate challenges." Mr. Elton continued: "At a projected 70% CO2 to fuel conversion efficiency, our technology can transform the 118,851 metric tons of annual CO2 emissions from the Capitol Power Plant into 12,479,355 gallons of gasoline. Using our technology, the U. S. Congress would not be forced to view CO2 emissions from its power plant as a $112 million taxpayer expense; but rather, a lucrative, sustainable and socially responsible revenue stream. Likewise, coal-fired power plants would not see pending CO2 legislation as a burden; but rather, a new and exciting business opportunity." About Carbon Sciences Inc.

Carbon Sciences Inc. is developing a breakthrough technology to transform carbon dioxide (CO2) emissions into fuels such as gasoline, diesel fuel, jet fuel and other portable fuels. Innovating at the intersection of chemical engineering and bio-engineering disciplines, we are developing a highly scalable biocatalytic process to meet the fuel needs of the world. Our solution to energy and climate challenges is a sustainable world of fuel consumption and climate stability by transforming CO2 into fuel. For example, Carbon Sciences` breakthrough technology can be used to transform CO2 emitted from fossil fuel power plants into gasoline to run cars and jet fuel to fly aircraft.

~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

Latest News ACTC Advanced Cell Technology, Inc.

ACTC Website Finance Stock Chart March 4th, 2009 Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that it has received a total of $400,000 in additional funding through the receipt of the final payment from CHA Biotech Co, Ltd., a leading Korean-based biotechnology company focused on the development of stem cell technologies, in connection with its recently formed international joint venture with Advanced Cell; and research grants from the National Institutes of Health. Proceeds from these transactions as well as other transactions in advanced discussions will be used to support the Company`s retinal pigment epithelium cells (RPE) program. The Company anticipates filing an IND with the FDA during the second half of this year.

"We continue to identify creative, non-dilutive ways to raise capital in a very challenging capital markets environment," said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. "We believe that investors are beginning to focus on the potential of our RPE program and its potential therapeutic impact on some 200 different retinal disease conditions. The immune privilege nature of the eye, coupled with a small dosage relative to other cellular therapies, plus the ease of application via a simple injection by needle makes this an ideal candidate for validating therapeutic applications for the human embryonic stem cell technology platform." About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. It`s laboratory is located in Worcester, Massachusetts.

~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

Latest News EESO Enzyme Environmental Solutions, Inc.

EESO Website Finance Stock Chart March 4th, 2009 Enzyme Environmental Solutions Inc. (PINKSHEETS: EESO) thanks shareholders nationwide who were in attendance at its February 27th Open House event.

"It was a true honor to have met new faces that define long-term support in EESO and its achievements," states Jared Hochstedler, CEO of the company who was very pleased with the turnout and feedback on last Friday`s gathering and is still touched by one moment in particular in which he was presented with an honorary framed U.S.

flag which was flown in Afghanistan during a combat mission. The flag was a gift from select soldiers from the 101st Airborne Division out of Fort Campbell, Kentucky.

101st is the lead element for US forces in Afghanistan assigned both to Operation Enduring Freedom - Afghanistan and the NATO-led International Security Assistance Force. The soldiers were among a few guests in attendance that stood up to share their own `EESO` stories in addition to staff such as Investor Relations, Mark B. Newbauer and a new addition to the EESO team, chemist, Frank Terranova, owner of his own private organic chemical development company, Novabella, Inc. Novabella is a multi faceted company offering the industry a one-stop shop to the knowledge, raw materials, components, products and formulation.

Frank was recently contracted to service EESO in development of new products and maintenance and upkeep of its current lines in regards to `Green` industry standards, which are "ever-changing." Terranova expands on his role: "I have been retained by EESO to help them understand and interpret the ever-changing regulations being established on Green products. I have been in this industry for over 27 years formulating and establishing standards for products and currently consult for several National Brand companies in relation to Green Product development. I believe strongly that my expertise will help EESO be a leader in the ongoing development of Green-Based Cleaning programs. They have only begun to tap their full potential on the commercial/industrial side and I am excited to be a part of the incredible path they are taking. Many products and product lines claim to be `Green` but can only maintain this claim with older classification standards. Some `Green` products are actually more harmful than the chemical-based products that EESO sets out to replace, and its important that people don`t just go out and purchase (for their home or business) a product that claims to be `green` or simply `contain enzymes` because Jared`s proprietary formulas are of the best I`ve seen in terms of being safe, effective and actually healing to the environment as they are used. I believe the Green Standards will continually change and be updated and I believe I bring depth to the knowledge we already had here at EESO, to keep us ahead of the curve in the regulations, but also to our new generation of formulations we can offer our customer base." In addition to Chemist, Frank Terranova, Enzyme Environmental, is currently interviewing candidates to take over Bill White`s role as VP of Sales and Operations as the business continues to thrive. White recently opted to part ways with the company, "(EESO`s) ever-evolving expansion requires an individual that can take this on with an appetite for Enzyme Environmental`s expansion goals and this requires frequent travel to Portage, IN and locations worldwide as they continue negotiations internationally.

I`m very proud of the success we`ve achieved as a team thus far and wish nothing but the best for Bill. It`s bittersweet, but I`m really looking forward to watching the company continue to thrive as Bill takes on some of his own personal and business goalsl." Hochstedler continues, "Finding a suitable replacement will be a meticulous process.

Bill was part of the team that took EESO to the next level and I think I speak for everyone here when I say he will be missed; but based on his needs and our own overall strategy, I feel this is a very important move for both parties. The transition will be seamless as we have contract personnel that are effective and efficient in overseeing current operations and vendor management until a replacement is selected.

The new VP of Sales and Operations will be instrumental in ramping up sales on our industrial/commercial licensing tech, particularly with the Pit Solution/FG-500 in odor and garbage remediation worldwide. Our timeline for this transition is approximately 2-3 weeks and everyone will be witness to a new sales force on the industrial/commercial side as we continue to grow." ~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

The Pot of Gold at the end of the Rainbow DLKM Douglas Lake Minerals, Inc.

DLKM Pot at The End of The Rainbow Website Finance Stock Chart TIGMR Site Feb 10th, 2009 Harp Sangha, CEO/President of Douglas Lake Minerals Inc. (OTCBB:DLKM / Frankfurt-D60.F) announces the results from the analytical assessment of 129 bulk samples from the Company`s wholly-owned Mkuvia Alluvial Gold Project - at 1.6 grams of gold per cubic meter.

"We are thrilled that our February results of 1.6 grams per cubic meter exceed our expectations, as the economic cut-off grade for Mkuvia is 0.20 grams," stated Harp Sangha. "The sampling of the Mkuvia alluvials took place in December, 2008 and was conducted by our Douglas Lake Tanzanian field crews. It consisted of a total of 129 measured 0.1 cubic metre samples of gold-bearing sand, and/or conglomerates.

These samples were processed in the field to produce heavy mineral concentrates.

These heavy mineral concentrates were split with a fraction of the concentrate generated from each sample, and then shipped to Eco-tech Laboratories in British Columbia for analysis". Details of the assay data from the Mkuvia Project can be viewed on Douglas Lake`s website.

These bulks sample results were derived as part of the same sampling program that confirmed that the Mkuvia project concentrates also contain significant amounts of platinum (see press release dated December 22, 2008). The analytical results from the assaying of the "splits" (fractions of the total concentrates recovered from individual samples) have been applied to total concentrate volumes to calculate gold grades per cubic metre. It should also be noted that the average gold grade in the conglomerates, which is the primary mining target, is 2.6 grams per cubic metre. The 2.6 grams is significantly higher than the average grade of the samples tested.

During the past six months, Douglas Lake`s ongoing exploration program has indicated a gold mineralization area of 6 km. by 29 km. by 10 meters in depth of approximately 1.74 billion cubic meters. Significant values of platinum, uranium and thorium have also been found, which should add to the economic value of the property. The mineralized area remains open for increases in gold mineralization in length, width and depth.

Currently, there are an additional 225 samples in for assay testing and the Company will release results as they are completed and assessed by our senior geologists.

Since purchasing 100% of the Southeastern Tanzania Mkuvia Project in June 2008, Douglas Lake`s management has believed the four prospecting licences have the potential to become a world-class alluvial gold producing mine not unlike the Witwatersrand Gold Rush of 1886 that led to the establishment of Johannesburg, South Africa.

After a brief Christmas hiatus and as the January rainy season ends, exploration work has commenced again. The Company cautions investors that ongoing sampling is required to ascertain a true average grade and fully assess the property`s potential.

About Our Strategic Partner Our strategic partner TIGMR, is a subsidiary of the China Geological Survey, a department of the Chinese Ministry of Land and Resources. The Institute assists the Chinese government with special geological projects conducted in China and throughout the world and has achieved numerous earth science accomplishments.

About Douglas Lake Minerals Inc.

DLKM is an emerging mineral exploration company focused on exploring and developing mining opportunities in Tanzania. The company has a large portfolio of gold, copper, nickel, uranium and diamond prospecting licenses.

~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

Latest News GOVX GeoVax Labs, Inc.

GOVX Website Finance Stock Chart Feb 20th, 2009 GeoVax Labs, Inc. (OTCBB: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced the first injections in its Phase 2a Human Clinical Vaccine Trial for its candidate HIV/AIDS vaccine. The trial, designated HVTN 205, is being conducted by the HIV Vaccine Trials Network (HVTN). The HVTN, funded and supported by the National Institutes of Allergy and Infectious Diseases (NIAID), is the largest worldwide clinical trials network dedicated to the development and testing of HIV/AIDS vaccines. The HVTN has sponsored over 80 Phase 1 trials for the initial evaluation of safety and immunogenicity of candidate HIV/AIDS vaccines.

The results of these trials have merited only five phase 2a trials since 1992. Progressing to Phase 2 is a significant step for GeoVax. The Company is pleased to report that the first injections for the Phase 2a trial were conducted at the HVTN network sites at the University of Alabama, Birmingham, and Vanderbilt University, Nashville.

The trial will include a total of 225 volunteers (150 vaccine recipients and 75 placebo recipients) and take place at 13 HVTN sites: 11 in North America and 2 in South America. Sites in the United States include Emory University, Atlanta; Harvard Medical School, Boston; Vanderbilt University, Nashville; University of Rochester; Fred Hutchinson Cancer Research Center, Seattle; the San Francisco Department of Public Health; University of Alabama, Birmingham and sites at Columbia University, Union Square, and the Bronx in New York City. In South America, participants are to be enrolled in Peru at sites in Iquitos and Miraflores (Lima).

"I am extremely pleased that our vaccine merited moving forward through the HVTN," said Harriet Robinson, Ph.D., developer of the vaccine and Senior V.P. of Research and Development at GeoVax. "This network provides a wide array of support for its clinical trials, from finances to statistical design and analysis; from community engagement to rigorous laboratory analysis. Working with the HVTN also affords us the input of the NIAID Prevention Science Research Committee, a committee with breadth of experience and knowledge in human vaccine development." GeoVax`s unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. Stimulation of both T cells and antibodies differentiates the GeoVax vaccine from many other vaccine candidates. GeoVax`s DNA and MVA vaccines are used in a prime-boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. These particles contain proteins that mimic more than half of the components of the AIDS virus, but cannot cause AIDS. This multi-protein approach is designed to elicit a broad multi-target protective T cell response. The Env protein is designed to elicit a protective Ab response against the natural form of the virus envelope glycoprotein as well as protective T cells.

Dr. Paul Goepfert, principal Investigator of HVTN 205 and director of the University of Alabama trial site, said, "The road to an effective vaccine to prevent HIV infection is long and winding. It is vital to continue testing promising products. I am very pleased to aid in the further development of this important product in a phase 2 trial." "For nearly 30 years since HIV/AIDS` discovery, researchers have been searching for a vaccine to combat its scourge," said Robert McNally, Ph.D., CEO and President of GeoVax Labs Inc. "Our Phase 1 trials found GeoVax`s vaccines to be safe and immunogenic in humans. Good results from the Phase 2a human trial will build upon this foundation of safety and immunogenicity to support a Phase 2b efficacy trial." In addition to the preventative vaccine entering Phase 2a, GeoVax also is working towards initiating human clinical trials testing its vaccines as potential therapies for people who are already infected with HIV. The goal of the therapeutic vaccination is to reduce the need of infected people for anti- viral drugs. Initial therapeutic trials will vaccinate infected people who are already on drugs to test the safety and immunogenicity of the vaccine in infected people. Therapeutic trials of a simian immunodeficiency virus (SIV) prototype of the GeoVax HIV vaccine in SIV infected primate animal models have held high promise that the GeoVax vaccine will be able to contribute to the control of HIV-1 in infected humans.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax`s AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already infected with AIDS virus.

GeoVax`s core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University`s Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007.

~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

Latest News NEOM NeoMedia Technologies, Inc.

NEOM(NEW) Website Finance Stock Chart Feb 18th, 2009 NeoMedia Technologies, Inc. (OTCBB: NEOM), the global leader in camera-initiated transactions for mobile devices, announced today that the United States Patent and Trademark Office (PTO) has ruled in favor of NeoMedia in the reexamination of its U.S. Patent No. 6,199,048, System And Method For Automatic Access Of A Remote Computer Over A Network. All ninety-five claims of this Barcode Lookup Patent have been confirmed as being patentable by the PTO.

The PTO`s re-validation of this patent provides tremendous opportunities for companies in the mobile advertising space, allowing them to unify and quickly move forward to implement new applications and services.

"This is excellent news for NeoMedia as it allows us to move forward with our vision to create strong partnerships and synergies to align all companies for the next growth phase," said Iain McCready, chief executive officer of NeoMedia Technologies, Inc. "We are committed to building a fully involved and collaborative ecosystem of agencies, mobile operators, and vendors who recognize the potential of mobile barcode advertising." "We are pleased that this patent has withstood the intense scrutiny of the PTO`s re-examination process, in which numerous additional prior art references were considered in detail by the PTO Examiners before confirming all ninety-five claims as being patentable", said Tony Barkume of Barkume & Associates, P.C., patent counsel for NeoMedia. "The approval indicated by the PTO in its Notice of Intent to Issue a Re-examination Certificate has confirmed the strength and validity of the `048 patent in the face of such a heightened challenge." In keeping with its vision and commitment to developing an interoperable global ecosystem, NeoMedia is licensing its technology to foster innovation in the creation of exciting new mobile barcode applications and services for the advertising industry.

NeoMedia embraces the development of open standards for 1D and 2D barcode technologies, and provides a global infrastructure to resolve these barcodes across multiple carriers.

The company`s ecosystem ensures that all parties involved in the transaction are accurately compensated by pre-defined business rules. Through NeoMedia`s complete solution, media & advertising companies, consumers, businesses, mobile operators and OEMs can harness wireless networks to perform commerce more easily and securely, and ensure monetization can occur reliably and accurately.

About NeoMedia Technologies NeoMedia Technologies, Inc. is the global leader in mobile barcode scanning solutions.

Our technology allows mobile devices with cameras to read 1D and 2D barcodes and provide "one click" access to mobile content. Combining this technology with advanced analytics and reporting capabilities revolutionizes the way advertisers market to mobile consumers. NeoMedia provides the infrastructure to make 2D camera barcode scanning and its associated commerce easy, universal, and reliable - worldwide.

The company`s mobile phone technology, NeoReader, reads and transmits data from 1D, and 2D barcodes to its intended destination. Our Code Management and Code Clearinghouse platforms create, connect, record, and transmit the transactions embedded in the 1D and 2D barcodes, like web-URLs, text messages (SMS), and telephone calls, ubiquitously and reliably. NeoMedia provides the industrial and carrier-grade infrastructure to enable reliable, scalable, and billable commerce. NeoMedia was founded in 1989, and is based in Atlanta, USA. It currently has 30 active patents spanning 13 countries, with 29 additional patents pending.

~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

"Green Play`s" are something that us here at Standout Stocks feel we should bring to the attention of all investors. These "Green Play`s" are not only beneficial for the investors but they benefit us all by producing "Environment Friendly" products and Alternative "Natural" Energy Sources.

So you can see why these "Green Play`s" are worth the time to take a look at. Remember these "Green Play`s" are definatly companies worth keeping an eye on to watch for the "Pop"! Standout Stock`s goal is to bring to you accurate, up-to-date news in a timely fashion. Standout Stocks has continuously been bringing you the biggest movers and shakers in the Small Cap and Micro Cap markets.

Spread the word! We would like to say "Thank You" to all of our subscribers and "Welcome" to our newest members! To ensure delivery of this service, please add mail@newmediaadvisorsllc.com to your e-mail address book Sincerely, The Standout Stocks Team! In This Issue CABN ACTC EESO DLKM GOVX NEOM Today`s Headlines ~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

Quick Links New Media Advisors Standout Stocks Penny Performers Businessweek FuturesMag.com FOXBusiness Forbes MSNMoney Nasdaq TSX Disclaimer ~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

GM:

Substantial doubt about survival March 5, 2009 8:22 AM ET GM`s Doubt General Motors Corp. said in a government filing Thursday that its accounting firm has found there is "substantial doubt" about the automaker`s ability to survive.

The embattled automaker made the disclosure in a 480-page filing with the Securities & Exchange Commission.

Full Story Here ~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

~~~~~~~~~~~~~~~~~~~~~~~~~~

About New Media Advisors

The emphasis of our company is on increasing investor awareness, share volume and share value. We are confident that these topics are cretainly of interest to you. Our concentration is in the area of working with emerging small and microcap companies. For support, we have two award winning sites that we utilize to help bring exposure to your company (Penny Performers and Standout Stocks).

Disclaimer: http://www.newmediaadvisorsllc.com/disclaimer.aspx

Contact: http://www.newmediaadvisorsllc.com/contact.aspx

See Standout Stocks's website for full disclaimer. Standout Stocks may have received compensation for stock picks.